RTM Vital Signs LLC (RTM) develops and commercializes real-time implantable cardiac and acoustic ventilation devices and monitoring systems. Their innovative, patented technology is designed to continuously monitor arterial blood pressure waveform and other vital sign data of ambulatory patients with cardiovascular disease (hypertension, ischemic heart disease, valve disease, arrhythmias and CHF) and ambulatory patients at risk for a serious adverse event. Physicians, nurses, and emergency personnel can now track recorded vital sign data, see trends, determine the etiology of new patient symptoms, and understand the effectiveness of medical therapy.
The long-term goal of RTM is to develop and commercialize a series of long-term implantable sensors capable of monitoring BP, blood flow, electrocardiogram, minute ventilation, hemoglobin oxygen saturation, core temperature, breath sounds/heart sounds, body position, and activity level in real-time.
A miniature, long-term monitoring system to improve hypertension & other cardiac issues.
A wearable, non-invasive acoustic sensor that accurately measures and monitors respiration.
A wearable device addressing the opioid crisis that saves lives & reduces healthcare costs.
A Looming Health Crisis
A new study released by the American Heart Association projects that by 2035, cardiovascular disease (CVD), a most costly and prevalent killer if left unchecked, will place a crushing economic and health burden on the nation’s financial and healthcare systems. According to the study, in the next two decades, the number of Americans with CVD will rise to 131.2 million – 45 percent of the total U.S. population – with costs expected to reach $1.1 trillion. In addition, there will be:
- 123.2 million Americans with high blood pressure
- 24 million coronary heart disease patients
- 11.2 million suffering from a stroke
- 7.2 million Americans with atrial fibrillation
Some other key findings:
- By age 45, your CVD risk is 50 percent, at 65 it jumps to 80 percent
- Black Americans will have the highest rates of CVD by 2035, followed by Hispanics
- Men will suffer from CVD at a greater rate than women between now and 2035